Bulletin
Investor Alert

NeuBase Therapeutics Inc.

NAS: NBSE

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 22, 2021, 6:40 p.m.

/zigman2/quotes/206101919/composite

$

4.48

Change

+0.44 +10.89%

Volume

Volume 1

Quotes are delayed by 20 min

/zigman2/quotes/206101919/composite

Previous close

$ 4.18

$ 4.04

Change

-0.14 -3.35%

Day low

Day high

$3.98

$4.22

Open

52 week low

52 week high

$3.26

$12.89

Open

Company Description

NeuBase Therapeutics, Inc. is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamm...

NeuBase Therapeutics, Inc. is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.

Valuation

Price to Book Ratio

5.62

Total Debt to Enterprise Value

0.00

Efficiency

Income Per Employee

-1,158,968.00

Liquidity

Current Ratio

10.42

Quick Ratio

10.42

Cash Ratio

10.16

Profitability

Return on Assets

-74.01

Return on Equity

-84.14

Return on Total Capital

-82.09

Return on Invested Capital

-84.14

Capital Structure

Total Debt to Total Equity

0.44

Total Debt to Total Capital

0.44

Total Debt to Total Assets

0.40

Officers and Executives

Name Age Officer Since Title
Dr. Dietrich A. Stephan 49 2018 Chairman & Chief Executive Officer
Dr. William R. Mann 60 2020 Chief Operating Officer
Mr. Robert Friedlander - - Consulting Chief Medical Officer
Dr. Curt W. Bradshaw - 2020 Chief Scientific Officer
Dr. Sandra Porcile Rojas-Caro 51 2021 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/18/2021 Dov A. Goldstein
Director
8,000   Acquisition at $4.75 per share. 38,000
04/26/2021 Dietrich A. Stephan
President and CEO; Director
12,000   Acquisition at $5 per share. 60,000
04/26/2021 Eric I. Richman
Director
5,000   Acquisition at $5 per share. 25,000
04/26/2021 Dov A. Goldstein
Director
12,000   Acquisition at $5 per share. 60,000
04/26/2021 William R. Mann
COO
5,000   Acquisition at $5 per share. 25,000
12/01/2020 Dietrich A. Stephan
President and CEO; Director
1,273,820   Gift at $0 per share. 0
12/01/2020 Dietrich A. Stephan
President and CEO; Director
1,273,819   Gift at $0 per share. 0
11/30/2020 Dietrich A. Stephan
President and CEO; Director
1,273,819   Gift at $0 per share. 0
11/23/2020 Dietrich A. Stephan
President and CEO; Director
2,547,639   Gift at $0 per share. 0
06/09/2020 Dietrich A. Stephan
President and CEO; Director
1,275   Acquisition at $7.73 per share. 9,855
05/21/2020 Dietrich A. Stephan
President and CEO; Director
1,250   Acquisition at $8.09 per share. 10,112
04/30/2020 Dietrich A. Stephan
President and CEO; Director
10,000   Acquisition at $6 per share. 60,000
04/30/2020 Eric I. Richman
Director
8,333   Acquisition at $6 per share. 49,998
04/30/2020 Eric I. Richman
Director
2,500   Acquisition at $6 per share. 15,000
04/30/2020 Dov A. Goldstein
Director
10,000   Acquisition at $6 per share. 60,000
04/30/2020 Samuel I. Backenroth
CFO, Treasurer & Secretary
1,000   Acquisition at $6 per share. 6,000
07/12/2019 Dietrich A. Stephan
President and CEO; Director
2,547,639   Award at $0 per share. 0
07/12/2019 Eric I. Richman
Director
25,247   Award at $0 per share. 0
04/10/2017 Samuel I. Backenroth
CFO, Treasurer & Secretary
71,429   Acquisition at $0.7 per share. 50,000
04/10/2017 AIGH Capital Management LLC
Director
171,429   Acquisition at $0.7 per share. 120,000
04/10/2017 Jason Scott Slakter
Chief Executive Officer; Director
142,858   Acquisition at $0.7 per share. 100,000
/news/latest/company/us/nbse

MarketWatch News on NBSE

  1. NeuBase Therapeutics started at outperform with $14 stock price target at Oppenheimer

    8:40 a.m. Nov. 21, 2019

    - Tomi Kilgore

  2. Carnegie Mellon University Is a Big Backer of This Biotech Stock

    7:00 a.m. July 27, 2019

    - Barron's Online

  3. Ohr Pharmaceutical downgraded to hold from buy at Brean Capital

    8:38 a.m. Aug. 10, 2016

    - Tomi Kilgore

  4. Charting the Market

    1:10 a.m. July 18, 2015

    - Barron's Online

  5. In focus: New highs seem unlikely

    6:33 p.m. July 15, 2015

    - Lawrence G. McMillan

  6. Three health-care deals today are paying huge premiums

    9:26 a.m. March 31, 2015

    - Philip van Doorn

  7. Charting the Market

    12:40 a.m. March 7, 2015

    - Barron's Online

  8. Charting the Market

    12:32 a.m. June 28, 2014

    - Barron's Online

/news/nonmarketwatch/company/us/nbse

Other News on NBSE

  1. Tracking David Einhorn's Portfolio - Q2 2021 Update

    2:00 a.m. Sept. 7, 2021

    - Seeking Alpha

  2. 10-Q: NEUBASE THERAPEUTICS, INC.

    4:14 p.m. Aug. 13, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  3. 10-Q: NEUBASE THERAPEUTICS, INC.

    6:09 a.m. May 14, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  4. NeuBase Therapeutics slumps on launching stock offering

    4:07 p.m. April 21, 2021

    - Seeking Alpha

  5. Tracking David Einhorn's Portfolio - Q4 2020 Update

    5:42 a.m. March 30, 2021

    - Seeking Alpha

  6. Neubase Therapeutics (NBSE) Investor Presentation - Slideshow

    12:42 p.m. March 18, 2021

    - Seeking Alpha

  7. 10-Q: NEUBASE THERAPEUTICS, INC.

    6:10 p.m. Feb. 11, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  8. NeuBase snaps gene modulating technology from Vera Therapeutics

    10:17 a.m. Jan. 28, 2021

    - Seeking Alpha

  9. Greenlight Capital Q4 2020 Letter

    3:27 p.m. Jan. 22, 2021

    - Seeking Alpha

  10. David Einhorn's Value Strategy Yields Results While Shorts Drag

    12:14 p.m. Jan. 22, 2021

    - GuruFocus.com

  11. 10-K: NEUBASE THERAPEUTICS, INC.

    5:34 p.m. Dec. 23, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  12. APHA, TLRY among premarket gainers

    9:25 a.m. Dec. 16, 2020

    - Seeking Alpha

  13. Tracking David Einhorn's Portfolio - Q3 2020 Update

    9:42 a.m. Nov. 18, 2020

    - Seeking Alpha

  14. Tracking David Einhorn's Portfolio - Q2 2020 Update

    8:49 a.m. Aug. 25, 2020

    - Seeking Alpha

  15. NeuBase Therapeutics appoints industry veteran as COO

    11:31 a.m. July 28, 2020

    - Seeking Alpha

  16. Loading more headlines...

At a Glance

NeuBase Therapeutics, Inc.

700 Technology Drive

Third floor

Pittsburgh, Pennsylvania 15219

Phone

1 646451790

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

09/2021

Revenue

N/A

Net Income

$-17.38M

Employees

15.00

/news/pressrelease/company/us/nbse

Press Releases on NBSE

  1. Friday Sector Laggards: Biotechnology, Publishing Stocks

    1:57 p.m. Oct. 15, 2021

    - MarketNewsVideo.com

  2. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.